An Introduction to Adaptive Randomisation in Clinical Trials [Video]

Adaptive randomisation in clinical trials is an approach where treatment allocation probabilities can change as evidence accumulates during a study. In this explainer, we break down how adaptive randomisation works, where it may be useful, and what teams need to control to keep the design scientifically and operationally robust.

What This Video Covers 
• What adaptive randomisation means in clinical trials  
• How response-adaptive randomisation and CARA differ  
• Why covariates, biomarkers, and predictive signals matter  
• Common risks, including delayed endpoints and time trends  
• When adaptive randomisation is a good fit, and when a simpler design may be more robust

Adaptive randomisation can be attractive when teams want to balance efficiency, ethics, and subgroup-specific learning. It also introduces real complexity, so strong governance, prespecified rules, timely data flow, and robust simulation work are essential.

At Quanticate, our biometrics teams support sponsors with rigorous, practical support across clinical trials and regulated development. Request a consultation today.